Loading
CoRegen
CoRegen develops a cell therapy made from a patient's own regulatory T cells, immune cells that normally calm the immune system, edited so that they help it attack cancer instead. Its first product is about to enter an early trial in breast and prostate cancer.
Overview
CoRegen, Inc. is based in Houston, Texas. Its platform knocks out a single gene, SRC-3, in regulatory T cells (Tregs) so that they stop suppressing anti-tumour immunity. CRG-150 is an autologous, gene-edited Treg cell therapy; the company says the FDA notified it in June 2026 that its CRG-150 study may proceed, and the phase 1/2a trial NCT07730125, with Baylor College of Medicine as collaborator, is planned in relapsed or refractory HR-positive HER2-negative breast cancer, triple-negative breast cancer and prostate cancer. The company's news page lists a July 2025 financing of more than 93 million US dollars and a March 2026 report of a further 13.5 million dollars. Its first registered cancer trial, NCT07730125, was posted on ClinicalTrials.gov in July 2026.
Headquarters
Houston, TX, US
Funding
All startupsGrowth stage
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Financing · Company news page headline: closes more than 93 million US dollar financing (9 July 2025). The GlobeNewswire release refused an automated fetch, so the round name and investors were not read. | 2025 | $93M | coregen.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Notes
- OnCo has no technology record for engineered regulatory T cell therapy, so no technology is linked. CRG-150 is not a CAR-T.
- Founding year not stated on the company website.
- The SRC-3 gene name comes from headlines on the company news page (SRC-3 engineered regulatory T cells); the release text was not read.
- A 13.5 million dollar amount appears only in a Houston Business Journal headline linked from the company news page and is not recorded as a funding row.
- Company website and news page read on 29 October 2026.
Connected
5Similar pages
- TreatmentVeliparib
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- Key paperGenomic characterization of metastatic breast cancers
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- BiomarkerTROP2 expression
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- TrialBROCADE3
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- TrialEMBRACA
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- BiomarkerHER2-low (IHC 1+ or IHC 2+/ISH-negative)
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- TrialOlympiAD
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
- TreatmentIpatasertib
Shares Metastatic triple-negative breast cancer, HR-positive / HER2-negative breast cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
coregen.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/